These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 15927364)
1. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Slack A; Lozano G; Shohet JM Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364 [TBL] [Abstract][Full Text] [Related]
2. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562 [TBL] [Abstract][Full Text] [Related]
3. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205 [TBL] [Abstract][Full Text] [Related]
4. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444 [TBL] [Abstract][Full Text] [Related]
5. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Slack A; Shohet JM Cell Cycle; 2005 Jul; 4(7):857-60. PubMed ID: 15917661 [TBL] [Abstract][Full Text] [Related]
6. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. He J; Gu L; Zhang H; Zhou M Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876 [TBL] [Abstract][Full Text] [Related]
7. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Gamble LD; Kees UR; Tweddle DA; Lunec J Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357 [TBL] [Abstract][Full Text] [Related]
8. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Gu L; Zhang H; He J; Li J; Huang M; Zhou M Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304 [TBL] [Abstract][Full Text] [Related]
9. p53 is a direct transcriptional target of MYCN in neuroblastoma. Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147 [TBL] [Abstract][Full Text] [Related]
10. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359 [TBL] [Abstract][Full Text] [Related]
11. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Jiang R; Xue S; Jin Z Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062 [TBL] [Abstract][Full Text] [Related]
12. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091 [TBL] [Abstract][Full Text] [Related]
14. The MYCN oncogene and differentiation in neuroblastoma. Westermark UK; Wilhelm M; Frenzel A; Henriksson MA Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159 [TBL] [Abstract][Full Text] [Related]
15. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458 [TBL] [Abstract][Full Text] [Related]
16. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633 [TBL] [Abstract][Full Text] [Related]
17. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881 [TBL] [Abstract][Full Text] [Related]
18. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436 [TBL] [Abstract][Full Text] [Related]
20. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Gupta A; Williams BR; Hanash SM; Rawwas J Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]